Drug prices in São Paulo's coast vary by up to 269%, Procon study finds
A survey by the Consumer Protection and Defense Program (Procon) in drugstores across Santos and São Vicente, on the coast of São Paulo, Brazil, revealed significant price discrepancies for medications, with variations reaching up to 269.4%. The study examined 68 different products from six companies, totaling 377 items, including 32 original and 36 generic drugs. Of these, 177 items were priced at or below the average. The research also indicated that generic medications are, on average, 59.88% cheaper than their reference counterparts. The most notable price difference was for a generic Tadalafil (5mg, 30 tablets), used for urethral stricture and erectile dysfunction, which ranged from R$21.50 to R$79.41. Among branded drugs, Amoxil (Amoxicillin 500g), an antibiotic requiring a prescription, showed the largest variation of 74.3%, with prices fluctuating between R$40.88 and R$71.22. Procon attributes these price fluctuations to market conditions, individual drugstore commercial strategies, and sales channels, noting that franchised chains may also have differing prices across their locations. Consumers are advised to check the batch number, manufacturing date, expiration date, and Ministry of Health registration before purchasing.
This price variation highlights the impact of market dynamics and commercial policies on essential goods. While competition can drive down prices, the wide disparities observed suggest potential inefficiencies in price discovery for consumers. The significant difference between generic and branded drugs underscores the value proposition of generics, yet the substantial range within both categories indicates that consumers may not always access the lowest available prices. Future market structures could potentially leverage technology to enhance price transparency and accessibility, ensuring more equitable access to medication based on factors beyond individual purchasing diligence.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.